Lead sponsor
Boehringer Ingelheim
8 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
8
Trials led
0
Ongoing
2,173
Total enrollment
236
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
6
Phase 2/3
1
Trials by status
Completed
6
Terminated
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.Study partner/caregiver requiredPh 2Completed611
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's TypeAlzheimer's diseasePh 2Completed430
Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer TypeAlzheimer's diseasePh 2Completed362
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.Study partner/caregiver requiredPh 2Completed329
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer TypeStudy partner/caregiver requiredPh 2/3Terminated198
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteersmild AD dementiaPh 1Completed61
Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer TypeAlzheimer's diseasePh 2Terminated54